Cetilistat, a new lipase inhibitor for the treatment of obesity.
Alizyme plc, in collaboration with Takeda Pharmaceutical Co Ltd in Japan, is developing cetilistat, an oral non-absorbed synthetic lipase inhibitor, derived from Alizyme's pancreatic lipase inhibitor research program, for the potential treatment of obesity in patients with or without diabetes. It is also under investigation for the potential management of type 2 diabetes. Several phase II clinical trials for obesity have been completed. Phase III trials were in preparation at the time of publication.
Padwal
Raj
R
University of Alberta, Clinical Pharmacology and Internal Medicine, 8440 112th Street, Edmonton, T6G 2B7, Canada. rpadwal@ualberta.ca
D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D048588:Benzoxazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008049:Lipase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015394:Molecular Structure; D009765:Obesity / Q000188:drug therapy* / Q000201:enzymology; D010330:Patents as Topic; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
D019440:Anti-Obesity Agents; D048588:Benzoxazines; D004791:Enzyme Inhibitors; D008049:Lipase; C520092:cetilistat